DelveInsight’s “Chronic Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Chronic Plaque Psoriasis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Chronic Plaque Psoriasis Market is an evolving segment of the global healthcare landscape, driven by the increasing Chronic Plaque Psoriasis prevalence of the disorder and the continuous development of innovative treatment options. The Chronic Plaque Psoriasis Market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.
Discover Key Insights into the Chronic Plaque Psoriasis Market with DelveInsight’s In-Depth Report @ Chronic Plaque Psoriasis Market Size
Key Takeaways from the Chronic Plaque Psoriasis Market Report
- In November 2024:- Zai Lab (Hong Kong), Ltd- A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical Gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis.
- In the 7MM, the US accounted for the highest prevalent cases of chronic plaque psoriasis in 2023, with around 6,425,000 cases; these numbers are expected to increase during the forecast period.
- In 2023, nearly 80% cases of chronic plaque psoriasis belonged to mild category.
- The leading Chronic Plaque Psoriasis Companies such as Alza Corporation, DE, USA, Momenta Pharmaceuticals, Almirall, S.A., UCB Biopharma SRL, Arcutis Biotherapeutics, Pfizer, Arcutis Biotherapeutics, Inc., Coherus Biosciences, Inc., Samsung Bioepis Co., Ltd., Alvotech Swiss AG, Mitsubishi Tanabe Pharma, ApoPharma, Cellceutix Corporation, Kadmon Corporation, LLC, Novartis, Coherus Biosciences, AbbVie, Astellas Pharma, Galderma R&D, UCB Biopharma SRL, and others
- Promising Chronic Plaque Psoriasis Therapies such as RWJ-445380, M923, LAS41008, Bimekizumab, Topical roflumilast, PF-06700841, ARQ-151 0.3% cream, CHS-1420, Humira (Adalimumab), Adalimumab, MT-1303, Apo805K1, Prurisol, Belumosudil, Secukinumab, Etanercept, Adalimumab, alefacept, Calcitriol 3mcg/g, Certolizumab pegol, and others.
Stay ahead in the Chronic Plaque Psoriasis Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Plaque Psoriasis Market Outlook
Chronic Plaque Psoriasis Epidemiology Segmentation
The chronic plaque psoriasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the Total Prevalent Cases of Plaque Psoriasis, Total Prevalent Cases of Chronic Plaque Psoriasis, Gender-Specific Prevalent cases of Chronic Plaque Psoriasis, Age-Specific Cases of Chronic Plaque Psoriasis, Severity Specific Cases of Chronic Plaque Psoriasis, and Total Treated Cases of Chronic Plaque Psoriasis
Download the report to understand which factors are driving Chronic Plaque Psoriasis epidemiology trends @ Chronic Plaque Psoriasis Prevalence
Chronic Plaque Psoriasis Marketed Drugs
- TALTZ (ixekizumab): Eli Lilly and Company
It is a humanized IgG4 monoclonal antibody that selectively binds with interleukin 17A (IL17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. TALTZ inhibits the release of pro-inflammatory cytokines and chemokines. The US FDA approved TALTZ (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasisin adult patients who are candidates for systemic therapy or phototherapy.
- SILIQ (brodalumab): AstraZeneca/Bausch Health
The US FDA approved SILIQ injection for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Siliq is an IL-17 receptor monoclonal antibody for patients with moderate-to-severe plaque psoriasis, a chronic, debilitating skin disease that causes red patches of skin covered with silvery scales.
Chronic Plaque Psoriasis Emerging Drugs
- TAK-279: Takeda
In September 2023, Takeda announced positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase IIb trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis.
Currently, a Phase III trial is being carried out in patients with Plaque Psoriasis to demonstrate how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis.
- ME3183: Meiji Seika Pharma
ME3183 is an orally-available and selective PDE4 inhibitor discovered by Meiji. In August 2023, Meiji Seika Pharma announced positive results in the Phase II study of ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, in patients with plaque psoriasis conducted in the United States and Canada.
- SGX302: Soligenix
SGX302 is a photodynamic light therapy for psoriasis treatment which uses synthetically manufactured hypericin applied as an ointment and activated with visible fluorescent light. In January 2024, Soligenix announced preliminary top-line results of its ongoing Phase IIa trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis.
Get In-Depth Knowledge on Chronic Plaque Psoriasis Market Trends and Forecasts with DelveInsight @ Chronic Plaque Psoriasis Treatment Market
Chronic Plaque Psoriasis Market Outlook
Psoriasis, a chronic relapsing disease, often requires long-term therapy, with treatment choices influenced by disease severity, comorbidities, and healthcare access. Patients are generally categorized as having mild or moderate-to-severe psoriasis. Mild cases are typically treated with topical agents like glucocorticoids, vitamin D analogs, and phototherapy, while moderate-to-severe cases may require systemic treatments, including biologics. Biologics, such as TNF inhibitors (e.g., adalimumab) and interleukin-targeting therapies (e.g., ustekinumab, secukinumab), have emerged as potent options, particularly when traditional therapies fail or are unsuitable. Despite the availability of biosimilars, their uptake, especially for infliximab, has been slow in the US. Studies show that treatment rates for psoriasis hover around 50-60%, with oral therapies gaining traction in recent years. Patients often switch therapies, with adalimumab being a common choice across multiple lines of treatment.
Scope of the Chronic Plaque Psoriasis Market
- Coverage- 7MM
- Chronic Plaque Psoriasis Companies- Alza Corporation, DE, USA, Momenta Pharmaceuticals, Almirall, S.A., UCB Biopharma SRL, Arcutis Biotherapeutics, Pfizer, Arcutis Biotherapeutics, Inc., Coherus Biosciences, Inc., Samsung Bioepis Co., Ltd., Alvotech Swiss AG, Mitsubishi Tanabe Pharma, ApoPharma, Cellceutix Corporation, Kadmon Corporation, LLC, Novartis, Coherus Biosciences, AbbVie, Astellas Pharma, Galderma R&D, UCB Biopharma SRL, and others
- Chronic Plaque Psoriasis Therapies- RWJ-445380, M923, LAS41008, Bimekizumab, Topical roflumilast, PF-06700841, ARQ-151 0.3% cream, CHS-1420, Humira (Adalimumab), Adalimumab, MT-1303, Apo805K1, Prurisol, Belumosudil, Secukinumab, Etanercept, Adalimumab, alefacept, Calcitriol 3mcg/g, Certolizumab pegol, and others.
- Chronic Plaque Psoriasis Market Dynamics: Chronic Plaque Psoriasis Market Drivers and Barriers
- Chronic Plaque Psoriasis Market Access and Reimbursement, Unmet Needs and Future Perspectives
Unlock Strategic Insights with DelveInsight’s Comprehensive Chronic Plaque Psoriasis Market Report @ Chronic Plaque Psoriasis Market Drivers and Barriers
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary of Chronic Plaque Psoriasis
4 Key Events
5 Chronic Plaque Psoriasis Epidemiology and Market Forecast Methodology
6 Chronic Plaque Psoriasis Market Overview at a Glance
7 Disease Background and Overview: Chronic Plaque Psoriasis
8 Chronic Plaque Psoriasis Treatment and Management
8.1 Treatment Guidelines and Recommendations
9 Epidemiology and Patient Population of Chronic Plaque Psoriasis in the 7MM
10 Chronic Plaque Psoriasis Patient Journey
11 Key Endpoints in Chronic Plaque Psoriasis
12 Chronic Plaque Psoriasis Marketed Therapies
13 Chronic Plaque Psoriasis Emerging Therapies
14 Chronic Plaque Psoriasis: Seven Major Market Analysis
15 Chronic Plaque Psoriasis Unmet Needs
16 SWOT Analysis
17 KOL Views
18 Market Access and Reimbursement
19 Appendix
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/